FMF-04-159-2

SKU: orb2815841

Description

FMF-04-159-2 is a covalent CDK14 inhibitor (IC₅₀=39.6 nM) that reduces α-synuclein aggregation in neuronal models of Parkinson's disease and suppresses triple-negative breast cancer progression in vitro and in vivo by inhibiting Wnt/β-catenin signaling.

Research Area

Cell Biology, Immunology & Inflammation, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2364489-81-4
• MW: 683.01
• Purity: 96.57% (May vary between batches)
• Formula: C₂₈H₃₀Cl₃N₇O₅S
• SMILES: N(C(=O)C1=C(Cl)C=C(Cl)C=C1Cl)C=2C(C(NC3CCN(S(=O)(=O)C4=CC(NC(/C=C/CN(C)C)=O)=CC=C4)CC3)=O)=NNC2
• Target: CDK,Others,Wnt/beta-catenin
• Solubility: DMSO:200 mg/mL (292.82 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (7.32 mM)

Bioactivity

• Target IC50:
  CDK2:256 nM (in NanoBRET assay)|CDK2:256 nM|CDK14-CyclinY:39.6 nM (in NanoBRET assay) |CDK14-CyclinY:39.6 nM
• In Vitro:
  FMF-04-159-2 can inhibit the proliferation of HCT116 cells with an IC50 of 1,144±190 nM.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

FMF 04 159 2, FMF041592, FMF-04-159-2, CDK2, CDK14/Cyclin Y

Compound Identifiers

PubChem CID

138454780